




COMPANY	PRODUCT PIPELINE	R&D	PARTNERING	INVESTOR RESOURCES	NEWS
-------------------------	----------------------------------	-------------------------	----------------------------	------------------------------------	----------------------

[management](#) | [board of directors](#) | [scientific advisory board](#)



NEWS

> [Press Releases](#)

> [Publications](#)

> [Articles](#)

> [Events](#)

Press Releases

> [Syngenta's Torrey Mesa Research Institute And Xencor Sign Research And License Agreement](#)

(BW Healthwire)--January 03, 2002---La Jolla, CA and Monrovia, CA.- January 3, 2002 - Torrey Mesa Research Institute (TMRI), a wholly owned subsidiary of Syngenta (NYSE: SYT), today announced the signing of a three year agreement with Xencor focusing on the discovery of novel proteins that will enable new products in the food, pharmaceutical and personal care industries.

Under the agreement, Xencor will use its patented Protein Design Automation(tm) (PDA (tm)) technology to create optimized versions of TMRI protein leads. Xencor will receive research support, as well as milestone payments and royalties on products commercialized from this research.

"We're pleased to be working with TMRI and its exceptional scientists and expanding into markets beyond pharmaceuticals and diagnostics," said Bassil Dahiyat, Ph.D., President and CEO of Xencor. "Our proprietary PDA technology elegantly merges supercomputing with experimental screening to overcome the limits of natural and directed evolution. By screening vastly more protein sequence diversity than possible with directed evolution methods, the PDA technology will create proteins with features tuned for TMRI's applications."

Xencor's PDA technology is the first method to combine advanced computational methods, high performance computing and experimental screening for protein optimization and sequence design. Xencor uses the information embedded in protein structure to optimize the function of a protein including its activity, binding affinity and specificity, stability, expression level, and potency.

"We are excited about the potential of Xencor's PDA technology to optimize the novel proteins that we have identified in our research," said Steven Briggs, Ph.D., President and CEO of TMRI. "This relationship will allow us to evaluate the PDA technology and extend the range of product development opportunities for Syngenta that are enabled by our genomics-based research programs."


Xencor, a privately held company, is focused on using its cutting edge protein analysis and optimization technologies to accelerate the discovery of therapeutic proteins and novel compounds. With its proprietary ProCode(tm) and Protein Design Automation(tm) (PDA(tm)) technologies, Xencor scientists can rapidly determine the interactions and functions of a cell's entire protein complement, identify proteins of interest, and then optimize key properties of these proteins to fit commercial applications. The use of these technologies alone, or in combination, will accelerate the compound identification and development programs of Xencor's strategic partners in the pharmaceutical, biotechnology, and agricultural and chemical industries. Further information is available at www.xencor.com.

The Torrey Mesa Research Institute is the genomics research center for Syngenta, a world leading agribusiness. Syngenta ranks first in crop protection, and third in the high-value commercial seeds market. Pro forma sales in 2000 were approximately US \$6.9 billion. Syngenta employs more than 20,000 people in over 50 countries. The company is committed to sustainable agriculture through Innovative Research and Technology. Formed in November 2000 by the merger of Novartis Agribusiness and Zeneca Agrochemicals, Syngenta is listed on the Swiss stock exchange, and in London, New York and Stockholm. Further information is available at www.syngenta.com.

This press release contains forward-looking statements, which can be identified by terminology such as "expect", "would", "will", "potential", "plans", "prospects", "estimated", "aiming", "on track", and similar expressions. Such statements may be subject to risks and uncertainties that could cause the actual results to differ materially from these statements. We refer you to Syngenta's publicly available filings with the U.S. Securities and Exchange Commission for information about these and other risks and uncertainties. Syngenta assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors. This release does not constitute, or form part of, any offer or invitation to sell or issue, or any solicitation of any offer, to purchase or subscribe for any ordinary shares in Syngenta AG, or Syngenta ADSs, nor shall it form the basis of, or be relied on in connection with, any contract therefore.



Copyright © 2005 Xencor, Inc. All rights reserved. Design



COMPANY

PRODUCT PIPELINE

R&D

PARTNERING

INVESTOR RESOURCES

NEWS

NEWS

NEWS

> Press Releases

> Publications

> Articles

> Events

Press Releases

> Xencor Announces Protein Optimization Collaboration with Lilly

Protein Design Automation® platform enables Medicinal Chemistry for Proteins™

Monrovia, CA – February 18, 2004 - Xencor today announced a collaboration with Eli Lilly and Company to optimize the physical and biochemical properties of a protein therapeutic. Xencor will use its proprietary Protein Design Automation® (PDA®) technology to create variants of the therapeutic protein that meet specific criteria for clinical development. Lilly will have the option to develop the resulting protein therapeutic candidates.

"This collaboration is an exciting opportunity to exploit our unique approach to controlling the physical and biochemical properties of a protein," said Bassil Dahiyat, Chief Scientific Officer of Xencor. "The PDA platform is a structure-based and systematic approach to optimize protein sequences for multiple properties that can lead to improvement in biological activity. As a result, we can now treat natural biotherapeutics as lead compounds and perform Medicinal Chemistry for Proteins™."

Harry Stylli, President and CEO of Xencor said, "Xencor is proud to work with Lilly on this focused but challenging project. This collaboration exemplifies Xencor's world class potential to resolve complex therapeutic challenges and create new intellectual property in the process."

About Protein Design Automation® technology

PDA® technology combines high performance computing with proprietary molecular biology processes and assays to create very broad protein diversity with exquisite control and efficiency. The technology takes advantage of the information embedded in protein structure to optimize key protein properties, such as binding affinity and selectivity, stability, and expression level, targeted to yield therapeutic proteins with enhanced safety and efficacy in the clinic. This process also creates new intellectual property, continually broadening Xencor's patent portfolio by generating sets of novel protein sequences that are distinct from naturally occurring proteins.

About Xencor

Xencor is a pre-clinical stage company that discovers and develops protein therapeutics using its proprietary rational protein design platform. Xencor's platform applies high performance computing and advanced molecular biology to rapidly discover drug candidates with novel mechanisms and improved safety and efficacy. Xencor is a privately held biopharmaceutical company located in Monrovia, CA. Additional information is available at www.xencor.com.

Press Releases

Articles

Publications

Events


Careers

Location

Copyright © 2005 Xencor, Inc. All rights reserved. Design



management | board of directors | scientific advisory board



NEWS

> Press Releases

> Publications

> Articles

> Events

Press Releases

> Xencor and Genentech to Collaborate to Develop Next-Generation Antibody Therapeutics

Genentech licenses Xencor's XmAb™ technology for CD20 and Her2, key cancer and autoimmune targets

Monrovia, CA—December 1, 2004 – Xencor today announced a license and collaboration agreement with Genentech, Inc. (NYSE: DNA) to create next-generation therapeutic antibodies for cancer and autoimmune diseases. Under the terms of the agreement, Xencor will grant to Genentech an exclusive, worldwide license to use Xencor's XmAb technology to develop and commercialize products directed against two clinically and commercially validated antibody targets, CD20 and Her2, and a third undisclosed antigen. Rituxan® (rituximab) targets CD20 and is marketed by Genentech and Biogen-Idec in the United States, Zenyaku in Japan and Roche in the rest of the world. Herceptin® (trastuzumab), which is marketed by Genentech in the United States and Roche in the rest of the world, targets the Her2 protein. The XmAb technology consists of a suite of proprietary engineered antibody Fc domains that can be incorporated into therapeutic candidates to potentially recruit the immune system's effector functions for the treatment of disease.

Xencor will receive an upfront fee of \$5 million and annual licensing fees. In addition, Xencor is eligible to receive pre-clinical, clinical and regulatory milestone payments for each collaboration target and royalties on sales of licensed products. No additional financial terms were disclosed.

"We are very excited to have Genentech as a partner using our XmAb technology to develop next generation antibody therapeutics against two such well-validated targets," said Harry Styli, Ph.D., President and CEO of Xencor. "Modulation of the immune system's effector functions holds the potential for improving efficacy and for benefiting a larger patient population. As a world leader in the development and commercialization of antibody therapeutics, Genentech has extensive experience in rapidly moving novel drug candidates to the clinic and ultimately the market to benefit patients. Also, by licensing our proprietary engineered Fc domains for use with these targets, this collaboration advances the licensing arm of our dual business strategy that also includes retaining rights for the internal development of other, select targets."

About XmAb™ Technology

Xencor has developed a suite of Fc variants to improve the therapeutic properties of monoclonal antibodies. Xencor's Fc variants can be inserted into therapeutic candidates against any target antigen and may improve one or more important effector functions, including enhanced antibody mediated tumor cell killing, improved half-life, and improved structural stability. XmAb antibodies are produced using conventional expression and manufacturing processes. Xencor has also restored effector functions in aglycosylated antibodies, thereby creating an opportunity to use alternative expression systems with the potential of significantly lower cost of goods.


About Xencor

Xencor, Inc. is a privately held biopharmaceutical company focused on the discovery and development of protein therapeutics for the treatment of cancer, inflammation and autoimmune disorders. Xencor applies its proprietary Protein Design Automation® technology to rapidly discover and develop novel proteins and next generation versions of existing biotherapeutics with improved safety and efficacy by optimizing such properties as binding affinity, specificity, stability, expression level and potency. Xencor is

developing antibodies with improved immune effector function and half-life, which are humanized and affinity matured using its proprietary technology. Xencor is also developing proprietary inhibitors of Tumor Necrosis Factor (TNF), a key target in arthritis and other rheumatic disorders. Xencor has collaborations with Eli Lilly and Company and Protein Design Labs. Additional information is available at www.xencor.com.



Copyright © 2005 Xencor, Inc. All rights reserved. Design



NEWS

> [Press Releases](#)

> [Publications](#)

> [Articles](#)

> [Events](#)

Press Releases

> [Xencor and Roche Collaborate for Optimized Antibodies](#)

Roche licenses Xencor's XmAb™ technology to enhance antibody efficacy

Monrovia, CA - January 12, 2005 - Xencor today announced a collaboration with Roche to create monoclonal antibodies with greatly enhanced potency. Roche will use Xencor's XmAb technology on a Roche antibody against a proprietary cancer target. The XmAb technology consists of a suite of engineered antibody Fc domains that can be applied to any antibody to control the recruitment of the immune system's effector functions and to increase antibody-mediated tumor killing.

Under the terms of the agreement, Xencor will receive technology access and license fees, and is eligible to receive additional license fees, milestones and royalties in the event that Roche advances candidates into development. Financial terms were not disclosed.

"We are excited that Roche, with a leading franchise in cancer monoclonal antibodies, will apply our XmAb technology to one of its antibody candidates," said Harry Stylli, Ph.D., President and CEO of Xencor. "The XmAb technology can be applied to any antibody in a plug-and-play fashion, thereby creating multiple collaboration and product opportunities. This collaboration with Roche extends our dual business strategy of licensing the XmAb technology for specific targets while retaining rights for the internal development of a portfolio of next-generation antibodies."



About XmAb™ Technology

Xencor has developed a suite of Fc variants to improve the therapeutic properties of monoclonal antibodies. Xencor's Fc variants can be inserted into therapeutic candidates against any target antigen and may improve one or more important effector functions, including enhanced antibody mediated tumor cell killing, improved half-life, and improved structural stability. XmAb antibodies are produced using conventional expression and manufacturing processes. Xencor has also restored effector functions in aglycosylated antibodies, thereby creating an opportunity to use alternative expression systems with the potential of significantly lower cost of goods.

About Xencor

Xencor, Inc. is a privately held biopharmaceutical company focused on the discovery and development of protein therapeutics for the treatment of cancer, inflammation and autoimmune disorders. Xencor applies its proprietary Protein Design Automation® technology to rapidly discover and develop novel proteins and next generation versions of existing biotherapeutics with improved safety and efficacy by optimizing such properties as binding affinity, specificity, stability, expression level and potency. Xencor is developing antibodies with improved immune effector function and half-life, which are humanized and affinity matured using its proprietary technology. Xencor is also developing proprietary inhibitors of Tumor Necrosis Factor (TNF), a key target in arthritis and other rheumatic disorders. Xencor has collaborations with Genentech, Eli Lilly and Company, Chugai Pharmaceutical Co. and Protein Design Labs. Additional information is available at www.xencor.com.





NEWS

[> Press Releases](#)[> Publications](#)[> Articles](#)[> Events](#)

Press Releases

[> Xencor and Chugai Initiate Partnership for Optimized Antibodies](#)*Chugai licenses Xencor's XmAb™ technology to enhance antibody efficacy*

Monrovia, CA – January 10, 2005 - Xencor today announced a license and collaboration agreement with Chugai Pharmaceutical Co., Ltd. (Chugai) to create monoclonal antibodies with greatly enhanced potency. Chugai will use Xencor's XmAb technology on Chugai's antibodies against a proprietary cancer target. The XmAb technology consists of a suite of engineered antibody Fc domains that can be applied to any antibody to control the recruitment of the immune system's effector functions and to greatly increase antibody-mediated tumor killing.

Under the terms of the agreement, Xencor will receive technology access and license fees, and is eligible to receive additional license fees, milestones and royalties in the event Chugai advances candidates into development. Financial terms were not disclosed.

"We are excited that Chugai, a leading pharmaceutical company with a history of success in protein and antibody therapeutics, is partnering with us to apply our XmAb technology in its antibody discovery efforts," said Harry Styli, Ph.D., President and CEO of Xencor. "The XmAb technology can be applied to any antibody in a plug-and-play fashion, thereby creating multiple collaboration and product opportunities. The Chugai collaboration furthers our strategy of licensing the XmAb technology to multiple partners for specific targets while retaining rights for the internal development of a portfolio of next-generation antibodies."


About XmAb™ Technology

Xencor has developed a suite of Fc variants to improve the therapeutic properties of monoclonal antibodies. Xencor's Fc variants can be inserted into therapeutic candidates against any target antigen and may improve one or more important effector functions, including enhanced antibody mediated tumor cell killing, improved half-life, and improved structural stability. XmAb antibodies are produced using conventional expression and manufacturing processes. Xencor has also restored effector functions in aglycosylated antibodies, thereby creating an opportunity to use alternative expression systems with the potential of significantly lower cost of goods.


About Xencor

Xencor, Inc. is a privately held biopharmaceutical company focused on the discovery and development of protein therapeutics for the treatment of cancer, inflammation and autoimmune disorders. Xencor applies its proprietary Protein Design Automation® technology to rapidly discover and develop novel proteins and next generation versions of existing biotherapeutics with improved safety and efficacy by optimizing such properties as binding affinity, specificity, stability, expression level and potency. Xencor is developing antibodies with improved immune effector function and half-life, which are humanized and affinity matured using its proprietary technology. Xencor is also developing proprietary inhibitors of Tumor Necrosis Factor (TNF), a key target in arthritis and other rheumatic disorders. Xencor has collaborations with Genentech, Eli Lilly and Company and Protein Design Labs. Additional information is available at www.xencor.com.





COMPANY	PRODUCT PIPELINE	R&D	PARTNERING	INVESTOR RESOURCES	NEWS
---------	------------------	-----	------------	--------------------	------



NEWS

> Press Releases

> Publications

> Articles

> Events

Press Releases

> Xencor and Protein Design Labs Initiate Partnership for Optimized Antibodies

PDL licenses Xencor XmAb™ technology to enhance antibody activity

Fremont, Calif. and Monrovia, Calif. – January 12, 2004 – Xencor and Protein Design Labs, Inc. (PDL) (Nasdaq: PDLI) today announced a licensing and collaboration agreement to create monoclonal antibodies with greatly enhanced potency. The multi-year collaboration will allow PDL to use Xencor's XmAb™ technology on a number of pre-clinical stage PDL antibodies against a number of PDL's proprietary targets. The XmAb™ technology consists of a suite of engineered Fc domains that can be applied to any antibody to control the recruitment of the immune system's effector functions and for oncology applications, to greatly increase antibody-mediated tumor killing.

Xencor will receive technology access and license fees, development milestones and royalties. PDL will be responsible for development and commercialization of the resulting products. Financial terms were not disclosed.

"Xencor is delighted that PDL, a leader in the discovery and development of antibody therapeutics, is partnering with us to apply the XmAb™ technology to a significant number of antibodies in a multi-year relationship," said Harry Styli, Ph.D., President and CEO of Xencor. "Xencor's Fc modifications recruit immune effector function greater than 100 times more potently than wild type antibodies and can be applied to any antibody in a plug-and-play fashion, thereby creating multiple collaboration opportunities. XmAb™ technology creates a new therapeutic dimension for antibodies that will be relevant for a range of disease areas including oncology, inflammation, transplantation and infectious diseases." Dr. Styli added, "We are establishing a leading IP position in controlling antibody interactions with the antibody receptor families that modulate the cell-based and complement arms of the immune system."

Mark McDade, Chief Executive Officer, PDL, said, "The Xencor partnership is an excellent fit within our overall research strategy. Our goal is to access a broad range of methodologies at the research stage that have potential to enhance antibody performance. We anticipate that the XmAb™ technology, in combination with our increasing pool of novel, cancer-tissue selective targets will complement and further extend our ability to exploit those targets, in the form of interesting new therapeutic approaches."

About XmAb™ Technology

Xencor is designing the constant Fc domains of monoclonal antibodies using Protein Design Automation® (PDA®) technology to improve their biochemical and cell biological characteristics, an approach applicable to antibodies against any target antigens. The XmAb™ platform improves numerous properties of antibodies including enhanced antibody mediated tumor cell killing, improvement of structural stability and reduced immunogenicity. The Company has created a suite of Fc variants with therapeutic properties such as improved tumor cell killing that can be inserted into any antibody.

About Xencor

Xencor is a preclinical-stage company that discovers and develops protein therapeutics using its proprietary rational protein design platform. Xencor's platform applies high performance computing and advanced molecular biology to rapidly discover drug candidates with novel mechanisms and improved safety and efficacy. Xencor is a privately held biopharmaceutical company located in Monrovia, Calif. Additional information is available at www.xencor.com.

About Protein Design Labs

Protein Design Labs is a leader in the development of humanized antibodies to prevent or treat various disease conditions. PDL currently has antibodies under development for autoimmune and inflammatory conditions, asthma and cancer. PDL holds fundamental patents for its antibody humanization technology. Further information on PDL is available at www.pdl.com.

With Regard to Protein Design Labs

The foregoing contains forward-looking statements involving risks and uncertainties and actual results may differ materially from those in the forward-looking statements. These risks and uncertainties include, but are not limited to, PDL's ability successfully to collaborate and develop potential products from the collaboration. Factors that may cause such differences are discussed in PDL's Annual Report on Form 10-K for the year ended December 31, 2002, in its quarterly report on Form 10-Q for the period ended September 30, 2003, and in other filings made with the Securities and Exchange Commission. The information in this press release is current as of its release date. PDL specifically disclaims any duty to update the information in this press release.

Protein Design Labs and Humanizing Science are registered U.S. trademarks and the PDL logo is a trademark of Protein Design Labs, Inc. XmAb™ technology is a trademark of Xencor.



Copyright © 2005 Xencor, Inc. All rights reserved. Design